Lipid Mediators in Transplantation Reperfusion Injury, Acute Rejection and Accelerated Transplant Atherosclerosis

  • Marie Foegh
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)


The function of the transplanted organ is influenced by three events, namely reperfusion injury, acute rejection and transplant vascular disease. The latter was previously called chronic rejection, and is now frequently referred to as transplant atherosclerosis (1).


Reperfusion Injury Acute Rejection Clonal Expansion Transplant Rejection Platelet Activate Factor Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. L. Foegh, Chronic rejection–Graft arteriosclerosis, Transpl. Proc. 22: 119–122 (1990).Google Scholar
  2. 2.
    J. V. Conte, N. M. Katz, R. B. Wallace, M. L. Foegh, Long term lung preservation with the PAF antagonist BN 52021, Transplantation, in press.Google Scholar
  3. 3.
    P. C. Corcoran, Y. Wang, N. M. Katz, S. S. Rajan, A. R. Analouei, M. L. Foegh, R. B. Wallace, Platelet activating factor antagonist enhances lung preservation in canine model of single lung allotransplantation, J. Thor. Cardiovasc. urg., in press.Google Scholar
  4. 4.
    P. J. Jacobsson, B. Odlauder, K. A. Yamaoka, A. Rosen, H. E. Claesson, Biosynthesis and biological effects of leukotriene B4 in B-lymphocytes, Adv. Prostaglandins, Thromboxane, Leukotriene Res. 21B: 1005–1012 (1991).Google Scholar
  5. 5.
    S. E. Dahlen, C. N. Serhan, Lipoxins: Bioactive lipoxygenase interaction products, p. 235–276, in: “Lipoxygenases And Their Products,” Academic Press, New York (1991).Google Scholar
  6. 6.
    M. L. Foegh, Immune regulation by eicosanoids, Transpl. Proc. 20: 1158–1161 (1988).Google Scholar
  7. 7.
    M. L. Foegh, E. Chambers, B. S. Khirabadi, T. Nakanishi, P. W. Ramwell, Platelet-activating factor in organ transplant rejection, Adv. Prostaglandins Thromboxane Leukotriene Res. 19: 377–382 (1989).Google Scholar
  8. 8.
    M. Rola-Pleszczynski, B. Pignol, C. Pouliot, P. Braquet, Inhibition of human lymphocyte proliferation and interleukin-2 production by platelet activating factor (PAFacether): Reversal by a specific antagonist, BN 52021, Biochem. Biophvs. Res. Commun. l42 (3): 754–60 (1987).CrossRefGoogle Scholar
  9. 9.
    M. I. McHugh, R. Wilkinson, R. W. Elliott et al., Immunosuppression with polyunsaturated fatty acids in renal transplantation, Transplantation 24: 263 (1972).CrossRefGoogle Scholar
  10. 10.
    G. F. Schreiner, W. Flye, E. Brunt, et al., Essential fatty acid depletion of renal allografts and prevention of rejection, Science 240: 1032 (1988).PubMedCrossRefGoogle Scholar
  11. 11.
    M. L. Foegh, B.S. Khirabadi, J. Rowles, P. Braquet, P. W. Ramwell, Prolongation of cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor, Transplantation 42: 86 (1986).PubMedGoogle Scholar
  12. 12.
    J. R. Rowles, M. L. Foegh ML, The synergistic effect of cyclosporine and iloprost on survival of rat cardiac allografts, Transplantation 42: 94 (1986).PubMedGoogle Scholar
  13. 13.
    M. L. Foegh, B. S. Khirabadi, P. W. Ramwell, Improved rat cardiac allograft survival with nonsteroidal pharmacologic agents related to eicosanoids, Transpl. Proc. 19 (1): 1297–1300 (1987).Google Scholar
  14. 14.
    M. L. Foegh, B. S. Khirabadi, R. Shapiro, M. R. Alijani, M. H. Goldman, R. R. Lower, P. W. Ramwell, Monitoring of rat heart allograft rejection by urinary thromboxane, Transpl. Proc. 16: 1606 (1984).Google Scholar
  15. 15.
    M. Foegh, J. F. Winchester, M. Zmudka, G. B. Helfrich, C. Cooley, P. W. Ramwell, G. E. Schreiner, Urinary iTXB2 in renal allograft rejection, Lancet 2: 431 (1981).PubMedCrossRefGoogle Scholar
  16. 16.
    L. K. Lim, M. R. Alijani, M. L. Foegh, Fine needle aspiration biopsy, serum B2-microglobulin, and urine thromboxane in renal allografts, Transpl. Proc. 21: 3583 (1989).Google Scholar
  17. 17.
    M. Kuwahara, J. Jacobsson, M. Kuwahara, E. Kagan, P. W. Ramwell, M. L. Foegh, Coronary artery ultrastructural changes in cardiac transplant atherosclerosis in the rabbit, Transplantation, in press.Google Scholar
  18. 18.
    M. L. Foegh, Chambers E, B. S. Khirabadi, T. Nakanishi, P. W. Ramwell, Platelet-activating factor in organ transplant rejection, Adv. Prostaglandin Thromboxane Leukotriene Res. 19: 377–382 (1989).Google Scholar
  19. 19.
    M. L. Foegh, B. S. Khirabadi, E. Chambers, S. Amamoo, P. W. Ramwell, Inhibition of coronary artery transplant atherosclerosis in rabbits with angiopeptin, an octapeptide, Atherosclerosis 78: 229–236 (1989).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Marie Foegh
    • 1
  1. 1.Department of SurgeryGeorgetown University Medical CenterUSA

Personalised recommendations